South Korea
· Delayed Price · Currency is KRW Hanmi Pharm. Statistics
Total Valuation
Hanmi Pharm. has a market cap or net worth of KRW 3.08 trillion. The enterprise value is 3.55 trillion.
| Market Cap | 3.08T |
| Enterprise Value | 3.55T |
Important Dates
The next estimated earnings date is Wednesday, April 30, 2025.
| Earnings Date | Apr 30, 2025 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
Hanmi Pharm. has 12.68 million shares outstanding. The number of shares has decreased by -0.09% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 12.68M |
| Shares Change (YoY) | -0.09% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 7.81% |
| Owned by Institutions (%) | 20.66% |
| Float | 6.20M |
Valuation Ratios
The trailing PE ratio is 21.47 and the forward PE ratio is 19.19.
| PE Ratio | 21.47 |
| Forward PE | 19.19 |
| PS Ratio | 2.06 |
| PB Ratio | 2.47 |
| P/TBV Ratio | 2.47 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 24.75 |
| EV / Sales | 2.37 |
| EV / EBITDA | n/a |
| EV / EBIT | 16.43 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.10
| Current Ratio | 1.10 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 12.23% and return on invested capital (ROIC) is 9.26%.
| Return on Equity (ROE) | 12.23% |
| Return on Assets (ROA) | 6.89% |
| Return on Invested Capital (ROIC) | 9.26% |
| Return on Capital Employed (ROCE) | 16.09% |
| Revenue Per Employee | 641.85M |
| Profits Per Employee | 61.59M |
| Employee Count | 2,330 |
| Asset Turnover | 0.76 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -26.80% in the last 52 weeks. The beta is 0.50, so Hanmi Pharm.'s price volatility has been lower than the market average.
| Beta (5Y) | 0.50 |
| 52-Week Price Change | -26.80% |
| 50-Day Moving Average | 260,920.00 |
| 200-Day Moving Average | 289,672.50 |
| Relative Strength Index (RSI) | 41.72 |
| Average Volume (20 Days) | 118,257 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Hanmi Pharm. had revenue of KRW 1.50 trillion and earned 143.50 billion in profits. Earnings per share was 11,316.84.
| Revenue | 1.50T |
| Gross Profit | 817.00B |
| Operating Income | 216.20B |
| Pretax Income | 173.10B |
| Net Income | 143.50B |
| EBITDA | n/a |
| EBIT | 216.20B |
| Earnings Per Share (EPS) | 11,316.84 |
Balance Sheet
| Cash & Cash Equivalents | n/a |
| Total Debt | n/a |
| Net Cash | n/a |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 1.25T |
| Book Value Per Share | 98,271.21 |
| Working Capital | 65.70B |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 54.63%, with operating and profit margins of 14.46% and 9.60%.
| Gross Margin | 54.63% |
| Operating Margin | 14.46% |
| Pretax Margin | 11.57% |
| Profit Margin | 9.60% |
| EBITDA Margin | n/a |
| EBIT Margin | 14.46% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 500.00, which amounts to a dividend yield of 0.20%.
| Dividend Per Share | 500.00 |
| Dividend Yield | 0.20% |
| Dividend Growth (YoY) | 150.00% |
| Years of Dividend Growth | 7 |
| Payout Ratio | n/a |
| Buyback Yield | 0.09% |
| Shareholder Yield | 0.29% |
| Earnings Yield | 4.66% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on December 27, 2023. It was a forward split with a ratio of 1.02.
| Last Split Date | Dec 27, 2023 |
| Split Type | Forward |
| Split Ratio | 1.02 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |